Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODE Systems Approach, Revised Guidance To Enhance Premarket Programs

This article was originally published in The Gray Sheet

Executive Summary

FDA has revised its guidance on early determination and agreement meetings to reassure sponsors that each meeting is not a "one-shot" opportunity.

You may also be interested in...



Given Imaging Guides Ingestible Microcapsule Through De Novo Process

Given Imaging hopes to be the second company to have a product cleared by way of FDA's de novo program this year by proposing to include several cautionary statements in the labeling of its wireless endoscopy diagnostic imaging system.

Given Imaging Guides Ingestible Microcapsule Through De Novo Process

Given Imaging hopes to be the second company to have a product cleared by way of FDA's de novo program this year by proposing to include several cautionary statements in the labeling of its wireless endoscopy diagnostic imaging system.

FDA Early Collaboration Guidance Offers Incentives For Formal Meetings

Device manufacturers have the option of postponing agreement meetings until informal "pre-meetings" with FDA are completed, according to a revised guidance outlining early collaborations under the FDA Modernization Act of 1997.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel